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Abstract
Metastatic osteosarcoma (OS) has a very poor prognosis. New treatments are therefore wanted.
The conditionally replicative adenovirus Ad5-∆24RGD has shown promising anti-tumor effects on
local cancers, including OS. The purpose of this study was to determine whether intravenous
administration of Ad5-∆24RGD could suppress growth of human OS lung metastases. Mice bearing
SaOs-lm7 OS lung metastases were treated with Ad5-∆24RGD at weeks 1, 2 and 3 or weeks 5, 6
and 7 after tumor cell injection. Virus treatment at weeks 1–3 did not cause a statistically significant
effect on lung weight and total body weight. However, the number of macroscopic lung tumor
nodules was reduced from a median of >158 in PBS-treated control mice to 58 in Ad5-∆24RGD-
treated mice (p = 0.15). Moreover, mice treated at weeks 5–7 showed a significantly reduced lung
weight (decrease of tumor mass, p < 0.05), a significantly increased body weight gain (decrease of
disease symptoms, p < 0.005) and a reduced number of macroscopic lung tumor nodules (median
60 versus > 149, p = 0.12) compared to PBS treated control animals. Adenovirus hexon expression
was detected in lung tumor nodules at sacrifice three weeks after the last intravenous adenovirus
administration, suggesting ongoing viral infection. These findings suggest that systemic
administration of Ad5-∆24RGD might be a promising new treatment strategy for metastatic
osteosarcoma.
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Osteosarcoma is the most prevalent non-hematological
primary malignant bone tumor. They can be subdivided
by location (medullary and surface) and by grade (high or
low grade). The vast majority of high-grade osteosarcoma
comprises of conventional osteosarcoma, but also
includes high-grade surface, telangiectatic and small-cell
osteosarcoma [1]. Patients with high-grade osteosarcoma
(OS) without evident metastatic disease at presentation
have 5-year survival of about 50–70% achieved by preop-
erative and postoperative chemotherapy with aggressive
surgery [2-6]. Patients presenting with overt metastatic
disease undergo the same pre- and postoperative chemo-
therapeutic regimen with resection of all metastases
whenever feasible. The majority of osteosarcoma metas-
tases are located in the lungs [4,7,8]. Multiple lung metas-
tases and bilateral distribution appear to be poor
prognostic factors for survival with 5-year overall survival
rates of 26% and 20%, respectively; in contrast to 75% for
a solitary lung lesion [8]. Moreover, OS patients that
relapse after first achieving complete surgical remission
during combined-modality chemotherapy have a 5-year
overall survival of 23% [9]. Long-term survivors were only
observed after a second surgical remission, indicating that
metastastectomy of all lesions is essential. The role of sec-
ond-line chemotherapeutic agents is unsure and might
result in limited improved outcome [9]. Clearly, for inop-
erable OS patients new treatment modalities are needed.
We explore the use of conditionally replicative adenovi-
ruses (CRAds) as a potential new treatment modality for
high grade OS and its lung metastases. Virus replication
will lyse tumor cells and released viral progeny can infect
neighboring tumor cells leading to lateral spread and
increased tumor cell kill. Previously we found that pri-
mary OS cells express low levels of the high affinity recep-
tor for adenoviruses, the coxsackie and adenovirus
receptor (CAR) [10,11]. In contrast, primary OS cells
express high levels of integrins [12]. To circumvent CAR
deficiency and thereby reduced tumor cell infectivity, we
use the CRAd variant Ad5-∆24RGD that carries a cyclic
Arg-Gly-Asp (RGD-4C) integrin binding motif in its fiber
knob domain [13]. This CRAd expresses mutant E1A that
cannot bind to pRb. Consequently, E2F, essential for viral
replication, is not released. Therefore, this CRAd is limited
to replicate in cancer cells with constitutively active E2F
and not in non-cycling normal cells with functional pRb
[14]. In vivo experiments showed that this virus induced
tumor regression of subcutaneous glioma, osteosarcoma
and cervical cancer tumors after intra-tumoral or systemic
administration [12,15-17]. Infection of CAR-deficient OS
cells with this integrin-targeted virus resulted in increased
infectivity and cell kill. Furthermore, we showed that
intra-tumoral administration of Ad5-∆24RGD in subcuta-
neous primary OS tumors resulted in a significant tumor
growth delay [12].
Local treatment of OS with CRAds has shown promising
results in animal models [12,18]. However, the major
challenge to cure OS patients depends on an effective
treatment for (non-resectable) metastases. Biodistribu-
tion studies in animals indicated that a considerable
amount of intravenously administered Ad5-∆24RGD is
delivered to the lungs (25% of the liver dose) [17]. In
addition, the RGD-modification might partially avoid
reduced infectivity as result of neutralizing antibodies
[19,20]. In the present study, we explore the use of intra-
venous administered Ad5-∆24RGD for the treatment of
OS lung metastases.
We first performed a pilot study in which mice were given
1 × 109 plaque forming units (pfu) intravenously once a
week for three consecutive weeks (3 × 109 pfu total). This
was the practically highest achievable dose and injection
of this amount of virus did not affect body weight, sug-
gesting that it did not induce overt toxicity. Therefore, this
dose was chosen to explore the anticancer potency against
OS lung metastases. SaOs-lm7 cells were injected intrave-
nously into mice to establish OS lung metastases [21]. In
a first experiment, mice bearing OS lung metastases were
treated with 1 × 109 pfu Ad5-∆24RGD or with PBS at
weeks 1, 2 and 3 after SaOs-lm7 injection. As parameter of
mouse well-being, their relative gain in body weight was
calculated. Ten weeks after tumor cell injection, mice were
sacrificed and their lungs dissected. Mouse lung weight
and number of macroscopic lung tumor nodules were
quantified to assess Ad5-∆24RGD anticancer effect. Mice
treated with Ad5-∆24RGD or PBS showed no significant
difference in body weight gain during the experiment
(data not shown). As shown in figure 1a, average lung
weight of virus treated animals appeared to be decreased
in comparison to PBS treated control animals, but this dif-
ference was statistically not significant (p = 0.15). Macro-
scopic appearance of the lungs reflected the lung weight
measurements, where a lower lung weight paralleled
fewer and smaller lung metastases and a higher lung
weight correlated with more and larger lung metastases
(figures 1b). In the PBS treated group, lungs often con-
tained numerous lung metastases; sometimes more than
could be counted (> 200). The median number of macro-
scopic tumor nodules on the lungs of PBS treated animals
was >158 (range 24 – >200). Lungs of Ad5-∆24RGD
treated animals carried a median number of 58 lung
metastases (range 26–155; figure 1c).
In a next experiment, we delayed the onset of oncolytic
adenovirus treatment by 4 weeks. Virus or PBS was
injected once per week at 5, 6 and 7 weeks after SaOs-lm7
tumor cell injection. Mice treated with Ad5-∆24RGDPage 2 of 6
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Therapeutic effect of Ad5-∆24RGD infusion 1–3 (left panel figure a & b) or 5–7 (right panel figure a & b) weeks after SaOs-lm7 injectionFigure 1
Therapeutic effect of Ad5-∆24RGD infusion 1–3 (left panel figure a & b) or 5–7 (right panel figure a & b) weeks after SaOs-lm7 
injection. (a) Effect of intravenous administration of Ad5-∆24RGD on OS pulmonary tumor burden. Lungs were removed and 
weighed. Open circles depict lung weight of each mouse and black lines show the median of each group. (b) Macroscopic 
appearance of dissected lungs. (c) Number of lung tumor nodules per mouse. (d) Immunohistochemical staining for expression 
of the adenovirus hexon protein in lungs of mice treated at weeks 5–7. Ten weeks after tumor cell injection and three weeks 
after the last virus injection lungs were isolated and analyzed for hexon expression. Representative pictures of the lungs from a 
PBS control mouse and two Ad5-∆24RGD treated mice (A & B) are shown at 10× and 40× magnification.
Molecular Cancer 2008, 7:9 http://www.molecular-cancer.com/content/7/1/9showed an average increase in weight of 18%, which was
significantly higher than the average 8% weight gain
observed for PBS treated control animals (P < 0.005).
Moreover, intravenous administration of Ad5-∆24RGD
resulted in a significant reduction of lung weight (median
241 mg) compared to PBS treated control animals
(median 723 mg; figure 1a; P < 0.05). The lung weight of
virus treated mice was just above normal mouse lung
weight (i.e., approximately 180 mg). The higher tumor
mass in the PBS treated group suggested that the total
body weight gain, after correction for increased tumor
mass, differed even more between the PBS and virus
treated animals. Also in this experiment, macroscopic
appearance reflected lung weight measurements (figure
1b). The median number of macroscopic lung metastases
(figure 1c) in PBS treated animals was >149 (range 4 –
>200) and in Ad5-∆24RGD treated animals 60 (range 0 –
172).
To strengthen the hypothesis that intravenous delivered
Ad5-∆24RGD caused an antitumor effect against OS lung
metastases, the lungs of mice from the second experiment
treated with Ad5-∆24RGD at weeks 5–7 and dissected at
week 10 were analyzed for adenoviral infection by hexon
staining. As shown in figure 1d, foci of infected cells were
present in SaOs-lm7 lung nodules, but not in normal lung
tissue. Thus, adenovirus infection could still be detected
in OS lung metastases 3 weeks after the last intravenous
Ad5-∆24RGD injection, supporting the assumption that
ongoing virus infection contributed to the beneficial
effects of systemic CRAd treatment. Adenovirus-positive
foci were not surrounded by apparent fibrosis, suggesting
that connective tissue barriers did not hamper intra-tumor
spread of the virus. However, such efficacy-limiting phys-
ical barriers might exist in OS.
In general, Ad5-∆24RGD treatment seemed to reduce lung
weight and number of macroscopic tumor nodules in
both tested treatment schedules. These parameters are
commonly used for therapeutic efficacy evaluation. Treat-
ment effects were most evident when virus treatment was
applied 5–7 weeks after tumor cell injection. Treatment at
week 5–7 also resulted in a significant body weight
increase, suggesting improved mouse well-being. More
insight into the kinetics of OS lung metastasis growth and
response to treatment could be obtained if longitudinal in
vivo imaging of SaOs-lm7 tumor growth would be possi-
ble. Unfortunately, a derivative reporter cell line for biolu-
minescent imaging is not available.
Together, our observations suggest that Ad5-∆24RGD is
active against OS lung metastases, which is in line with
recent finding by Li et al [22], who showed that a tran-
scriptional replication-competent adenovirus (AdOC-
E1a) reduced the number of OS lung tumor nodules. Fur-
thermore, our experiments suggest that timing of virus
injection influences treatment outcome. A possible expla-
nation for the more effective outcome in mice treated at
weeks 5–7 might be found in a dependence on an estab-
lished tumor vasculature for systemic CRAd delivery.
SaOs-lm7 injected tumor cells will form microscopic lung
metastases by 3–5 weeks and visible lung nodules by 6
weeks [21]. Microscopic tumors are usually in a pre-vascu-
lar state and only growth beyond 2–3 mm3 requires blood
vessel formation [23]. Virus injected at week 1–3 thus pre-
sumably treats isolated tumor cells or microscopic tumor
nodules, which could be reached via diffusion, whereas
treatment at week 5–7 would allow vascular delivery to
macroscopic tumor nodules. Although we documented
significant therapeutic efficacy after three injections of
Ad5-∆24RGD, mice were not completely cured from their
OS lung metastases. To increase treatment efficacy
extended administration schemes could be tested. In addi-
tion, in a clinical setting in humans isolated lung per-
fusion to increase CRAd delivery could be considered.
Several clinical trials delivering therapeutic agents to sar-
coma lung metastases via isolated lung perfusion have
been conducted [24]. Clinical trials with Ad5-∆24RGD for
the treatment of glioma and ovarian cancer are developed
and will be started soon [25]. These studies will provide
valuable data on the safety profile of this CRAd in humans
important to pursue development of Ad5-∆24RGD for OS
and OS lung metastases treatment.
Methods
Cell lines
SaOs-lm7 cells are derived from SaOs-2 human OS cells
by repetitive cycling through the lungs of nude mice [21].
SaOs-lm7 cells are grown in Eagle's minimal essential
medium supplemented with nonessential amino acids,
sodium pyruvate, L-glutamine, 10% fetal calf serum (FCS)
and 50 IU/ml penicillin plus 50 µg/ml streptomycin (PS;
Life Technologies, Breda, the Netherlands). Cultures are
maintained and harvested at sub-confluence. A549 and
293 cells were obtained from the American Type Culture
Collection (Manassas, VA) and are maintained in F12-
supplemented Dulbecco's modified Eagle's medium
(DMEM) with 10% FCS and PS. All cells are cultured at
37°C in a humidified, 5% carbon dioxide atmosphere.
Recombinant adenoviruses
The CRAd Ad5-∆24RGD lacks 24 base pairs encoding 8
amino acids in the pRb binding domain of E1A and car-
ries a cyclic RGD epitope in the HI-loop of the fiber [13].
This CRAd was propagated on A549 cells. Virus was puri-
fied using cesium chloride gradient banding. Functional
titers in pfu were determined by end-point limiting dilu-
tion on 293 cells.Page 4 of 6
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Female athymic/nude/nude mice were purchased from
Harlan (Horst, the Netherlands). Animals were main-
tained under pathogen-free conditions and fed a standard
laboratory diet ad libitum. All experiments were approved
by the local committee on animal experiments and were
carried out under the conditions established by the Euro-
pean Community (directive 86/609/CCE). Mice were
injected with 5 × 106 SaOs-lm7 cells in the lateral tail vein
in 200 µl Hanks Balanced Salt Solution w/o calcium and
magnesium. Intravenous injection of SaOs-lm7 cells
results in microscopic lung metastases by week 3–5 and
macroscopic disease at 6 weeks.
Intravenous administration of Ad5-∆24RGD to mice 
bearing osteosarcoma lung metastases
In two independent experiments, 12 mice bearing SaOs-
lm7 lung metastases were randomly divided into 2 groups
of each 6 mice. Mice were treated three times, in weeks 1,
2, and 3 (experiment 1) or in weeks 5, 6 and 7 (experi-
ment 2). The first group received intravenous injections in
the tail vein of 1 × 109 pfu Ad5-∆24RGD in 200 µl PBS and
the second control group received 200 µl PBS.
Body weight was measured twice a week. All mice were
sacrificed in week 10 after tumor cell injection. The lungs
were removed in toto without difficulty and photo-
graphed. Two researchers counted tumor nodules on the
outside of the lungs independently and the average of the
two measurements was calculated. Lungs were snap fro-
zen in liquid nitrogen and weighed using a Mettler H31 (±
0.1 mg; Mettler-Toledo International Inc).
Immunohistochemical analysis
Cryosections of lungs obtained at week 10 from mice
treated at weeks 5, 6 and 7 after tumor cell injection were
fixed in acetone. Immunohistochemical staining for ade-
novirus (hexon) was done using goat anti-adenovirus
antibody 1056 (Chemicon International, Temecula, CA).
Sections were then incubated with biotinylated goat anti-
rabbit IgG antibodies. The immune reaction was visual-
ized using the streptavidin-biotin-Horse Radish peroxi-
dase complex method (StrepABComplex/HRP; Dako,
Glostrup, Denmark) followed by diaminobenzidine solu-
tion (Vector Laboratories, Inc., Burlingame, CA). Sections
were counterstained with hematoxylin (Sigma Aldrich, St.
Louis, MO), dehydrated and mounted.
Statistical analysis
Differences in relative gain in mouse weight, number of
lung metastases and total lung weight between treatment
groups were analyzed with a two and one-tailed Mann-
Whitney test, respectively, using GraphPad Instat 3.0
(GraphPad Software, Inc., San Diego, CA).
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